# Presidential Report: Reversing Heart Failure via Closed-Loop Pharmacological Control

## Executive Summary
Heart failure is a systemic collapse of the RAAS (Renin-Angiotensin-Aldosterone System) and SNS (Sympathetic Nervous System) axes. We are moving beyond the 'standard of care' to a **Closed-Loop Pharmacological Implant** that dynamically balances these axes in real-time to reverse cardiac remodeling.

## Integration with HeartFailureTrajectory.ts

The `HeartFailureTrajectory.ts` aggregate serves as the AI's decision engine. It monitors the patient's B-type Natriuretic Peptide (BNP) levels and cardiac output via an implanted biosensor.

### The Control Loop
1. **Sensing**: The implant measures BNP, potassium, and creatinine levels every 60 seconds.
2. **Analysis**: The AI compares the current trajectory against the 'Optimal Recovery Curve' defined in `HeartFailureTrajectory.ts`.
3. **Actuation**: The implant contains micro-reservoirs of ACE inhibitors, Beta-blockers, and SGLT2 inhibitors. The AI releases precise nanogram doses based on the current state of the RAAS/SNS axis.
4. **Reversal**: By preventing the 'over-compensation' of the SNS, the AI stops the fibrotic process and allows the myocardium to undergo reverse remodeling.

## Policy Failure: The Chronic Care Trap
Democratic healthcare policies have created a 'Chronic Care Trap,' where patients are kept in a state of stable failure rather than being pushed toward recovery. This is a financial model for insurance companies, not a medical model for humans.

## Empirical Basis
- **BNP Monitoring**: BNP is a clinically validated marker of ventricular stretch and heart failure severity.
- **Closed-Loop Delivery**: Based on the architecture of insulin pumps, applied here to the complex neurohormonal axis of the heart.